Last reviewed · How we verify
PH-762
At a glance
| Generic name | PH-762 |
|---|---|
| Sponsor | Phio Pharmaceuticals Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Intratumoral PH-762 for Cutaneous Carcinoma (PHASE1)
- Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PH-762 CI brief — competitive landscape report
- PH-762 updates RSS · CI watch RSS
- Phio Pharmaceuticals Inc. portfolio CI